Accelerant Sets Special Meeting to Vote on Thoma Bravo's $20.25 Cash Buyout
ARX has more than doubled off its 52-week low of $9.18 on light trading volume (0.2× avg).
Summary
Accelerant filed the preliminary proxy for its $20.25-per-share cash sale to Thoma Bravo, setting a special meeting where ACP's locked-in votes alone can approve the deal; the go-shop produced no rival bid and most regulatory clearances are in hand.
Key Events · M&A and Partnerships · ARX
-
Special Meeting Set for $20.25 Cash Merger
Shareholders will vote on a special resolution to adopt the Thoma Bravo merger at $20.25 per share in cash, plus a ticking amount if closing is delayed; the board and special committee unanimously recommend approval.
-
ACP Votes Alone Can Approve Deal
Approval needs two-thirds of votes cast, and the ACP Shareholders' voting and support agreement covers enough shares to approve the merger without any other shareholder's vote.
-
Go-Shop Closed With No Rival Bid
The 40-day go-shop expired September 22, 2026 with no Excluded Person submitting an Acquisition Proposal or indicating renewed interest; the company is now in a customary no-shop with a fiduciary out.
-
Regulatory Gates Narrowing
HSR early termination was granted September 21, 2026, Belgium cleared the deal October 26, 2026 and Australia's ACCC granted a waiver October 27, 2026; Italian Golden Power and state insurance approvals (Texas, Arkansas, Puerto Rico, Cayman, UK) remain outstanding.
Analysis · ARX · Finance
The market already knows the headline: Thoma Bravo pays $20.25 a share in cash, roughly 49% above the $13.61 close on August 12, 2026, the last trading day before announcement. What this proxy adds is the machinery around the vote. Because ACP's support agreement alone covers enough shares to clear the two-thirds-of-votes-cast threshold, approval is effectively locked. The go-shop came and went with no competing bid, and antitrust and foreign-investment clearances have been falling into place (HSR early termination September 21, Belgium October 26, Australia October 27), leaving Italian Golden Power and the state insurance approvals as the remaining gates. Note that the ticking fee of $0.00333 per share per day only starts once everything except specified insurance approvals is done, so it compensates holders for regulatory drag rather than adding value. With the stock at $19.82 against $20.25 in cash, the spread is thin and the trade is now about deal timing, not price.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARX was trading at $19.82 on NYSE in the Finance sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $9.18 to $19.90. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.